Sandbox Reserved 1170: Difference between revisions

Line 33:

=== Other Potential Inhibitors ===

[[Image:AMG-837.jpg |300 px|right|thumb|Figure 5. Structure of the potential agonist AMG-837. In clinical trials, this drug was found to increase glucose tolerance in individuals with Type 2 Diabetes.]] TAK-875 had the most promising outlooks out of any current known agonists of hGPR40, but it was discontinued. Some other agonists tested in clinical trials include AMG-837 and AM-1638. When coadministered, AMG-837 (Figure 5) and AM-1638 enhanced glucose tolerance, but they were found to be toxic in the human trials. Some other agonsits are currently being examined as well. One compound, LY 2881835, has undergone clinical trials, but the results are unknown. In addition to the above-mentioned compound, other orally bioavailable GPR40-specific agonists are currently in preclinical or clinical development. As of 2015, TUG-770 and CNX-011-67 (Connexios Life Sciences, Karnataka, India) were in preclinical trials and JTT-851 (Japan Tobacco, Toyko, Japan), and P11187 (Piramal, Mumbai, India) were in clinical trails.

[[Image:AMG-837.jpg |300 px|right|thumb|Figure 5. Structure of the potential agonist AMG-837. In clinical trials, this drug was found to increase glucose tolerance in individuals with Type 2 Diabetes.]] TAK-875 had the most promising outlooks out of any current known agonists of hGPR40, but it was discontinued. Some other agonists tested in clinical trials include AMG-837 and AM-1638. When coadministered, AMG-837 (Figure 5) and AM-1638 enhanced glucose tolerance, but they were found to be toxic in the human trials. Some other agonsits are currently being examined as well. One compound, LY 2881835 (Eli Lilly & Company, Indianapolis, IN), has undergone clinical trials, but the results are unknown. In addition to the above-mentioned compound, other orally bioavailable GPR40-specific agonists are currently in preclinical or clinical development. As of 2015, TUG-770 and CNX-011-67 (Connexios Life Sciences, Karnataka, India) were in preclinical trials and JTT-851 (Japan Tobacco, Toyko, Japan), and P11187 (Piramal, Mumbai, India) were in clinical trails.

Sandbox Reserved 1170: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

Revision as of 15:50, 15 April 2016 view source Whitney Hart (talk \| contribs) 186 edits No edit summary ← Older edit		Revision as of 15:51, 15 April 2016 view source Whitney Hart (talk \| contribs) 186 edits No edit summary Newer edit →
Line 33:		Line 33:

	=== Other Potential Inhibitors ===		=== Other Potential Inhibitors ===
	[[Image:AMG-837.jpg \|300 px\|right\|thumb\|Figure 5. Structure of the potential agonist AMG-837. In clinical trials, this drug was found to increase glucose tolerance in individuals with Type 2 Diabetes.]] TAK-875 had the most promising outlooks out of any current known agonists of hGPR40, but it was discontinued. Some other agonists tested in clinical trials include AMG-837 and AM-1638. When coadministered, AMG-837 (Figure 5) and AM-1638 enhanced glucose tolerance, but they were found to be toxic in the human trials. Some other agonsits are currently being examined as well. One compound, LY 2881835, has undergone clinical trials, but the results are unknown. In addition to the above-mentioned compound, other orally bioavailable GPR40-specific agonists are currently in preclinical or clinical development. As of 2015, TUG-770 and CNX-011-67 (Connexios Life Sciences, Karnataka, India) were in preclinical trials and JTT-851 (Japan Tobacco, Toyko, Japan), and P11187 (Piramal, Mumbai, India) were in clinical trails.		[[Image:AMG-837.jpg \|300 px\|right\|thumb\|Figure 5. Structure of the potential agonist AMG-837. In clinical trials, this drug was found to increase glucose tolerance in individuals with Type 2 Diabetes.]] TAK-875 had the most promising outlooks out of any current known agonists of hGPR40, but it was discontinued. Some other agonists tested in clinical trials include AMG-837 and AM-1638. When coadministered, AMG-837 (Figure 5) and AM-1638 enhanced glucose tolerance, but they were found to be toxic in the human trials. Some other agonsits are currently being examined as well. One compound, LY 2881835 (Eli Lilly & Company, Indianapolis, IN), has undergone clinical trials, but the results are unknown. In addition to the above-mentioned compound, other orally bioavailable GPR40-specific agonists are currently in preclinical or clinical development. As of 2015, TUG-770 and CNX-011-67 (Connexios Life Sciences, Karnataka, India) were in preclinical trials and JTT-851 (Japan Tobacco, Toyko, Japan), and P11187 (Piramal, Mumbai, India) were in clinical trails.